LISCure Biosciences creates a new therapeutic paradigm with
microorganism-based medicines.

COMPANY

The Great Pioneer for Incurable Diseases The Great Pioneer for Incurable Diseases

LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”

LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”

TECHNOLOGY

Innovative Platform Technology Based on Microbiology and Genomics Innovative Platform Technology Based on Microbiology and Genomics

The LMT (LISCure Microbiology-based Technology) platform is used to discover and analyze microorganism-based drug candidates. It consists of a therapeutic screening platform, a microbial optimization platform, and a microbiome database platform.

PIPELINE

Addressing Areas of High Unmet Medical Needs Including Oncology, Liver Diseases, Neuroscience, and Immunology Addressing Areas of High Unmet Medical Needs Including Oncology, Liver Diseases, Neuroscience, and Immunology

We are conducting a number of global clinical trials, and we have partnered with reputable research institutes, such as Mayo Clinic and Scripps Research, to jointly research and develop liver disease and immuno-oncology programs.

  • Indication
  • Product
  • Collaborators
  • Discovery
  • In-Vivo Efficacy
  • IND Enabling
  • Phase 1
  • Phase 2
  • Microbiome Therapeutics
  • LIVER DISEASES
    LIVER DISEASES
    IMMUNOLOGY
    NEUROSCIENCE
    LIVER DISEASES
  • LB-P8
    LB-P8
    LB-P6
    LB-P4
    LB-P7

    NASH & NAFLD

    2022

    Cholestatic Liver Disease

    2023

    Auto-immune Disease

    2023

    Parkinson’s Disease/Alzheimer’s Disease

    2023

    Combination Studies

  • Bacteria-mediated
    Immunotherapy
  • ONCOLOGY
  • LB-P2D
    LB-P1
    LB-P3
    LB-P10
    LB-P11

    Solid Tumors (metastatic cancers)

    2022

    Solid Tumors

    Solid Tumors

    Solid Tumors

    Solid Tumors

  • Bacterial EV
  • NEUROSCIENCE
    IMMUNOLOGY
  • LB-P4E
    LB-P6E
  1. Research Collaboration
  2. 01. Research Collaboration with Mayo Clinic (LB-P7&P8 NASH)
  3. 02. Research Collaboration with Mayo Clinic (LB-P8 Rare Liver Diseases)
  4. 03. Research Collaboration with The Scripps Research Institute (LB-P2D Immuno-Oncology)